Sitagliptin therapy enhances the number of circulating angiogenic cells and angiogenesis—evaluations in vitro and in the rat critical limb ischemia model

MUIR > Graduate Institute of Health Care > Department of Nursing > Papers > Item 987654321/2520

Please use this identifier to cite or link to this item: http://ir.meiho.edu.tw/ir/handle/987654321/2520

Title:	Sitagliptin therapy enhances the number of circulating angiogenic cells and angiogenesis—evaluations in vitro and in the rat critical limb ischemia model
Authors:	SARAH CHUA;JIUNN-JYE SHEU;YUNG-LUNG CHEN;LI-TEH CHANG;CHEUK-KWAN SUN;STEVE LEU;HSIN-CHING SUNG;TZU-HSIEN TSAI;SHENG-YING CHUNG;KUO-HO YEH;CHUNG-LUNG CHO;YING-HSIEN KAO;HON-KAN YIP
Keywords:	angiogenesis;endothelial progenitor cells;laser Doppler blood flow;sitagliptin
Date:	2013
Issue Date:	2014-09-15T06:49:19Z (UTC)
Abstract:	Background aims. We tested the hypothesis that sitagliptin is capable of increasing blood flow in the rat critical limb ischemia (CLI) model by enhancement of angiogenesis. Methods. Adipose tissue from adult-male Fischer 344 rats (n ¼ 6) were cultured in endothelial progenitor cell culture medium for 14 d with (25 mmol/L) or without sitagliptin. CLI was induced by ligation of the left femoral artery. Rats (n ¼ 32) were equally separated into four groups: untreated controls (group 1), sitagliptin (4 mg/kg per day; group 2), CLI (group 3) and CLI with sitagliptin (group 4). Results. In vitro, 7 and 14 d after cell culture, endothelial progenitor cell biomarkers assessed by flow cytometry (Sca-1/CD31þ, CXCR4þ, c-kitþ and CD34þ cells) and Western blot (vascular endothelial growth factor, CXCR4 and stromal-derived factor [SDF]-1a) were remarkably higher in group 4 than in the other groups (all P < 0.01). In vivo, 2 and 14 d after the CLI procedure, circulating angiogenic cell (Sca-1/CD31þ, Sca-1þ and CD31þ) numbers were significantly higher in group 4 than in the other groups (all P < 0.001). Additionally, the messenger RNA and protein expression of angiogenic biomarkers (CXCR4, SDF-1a and vascular endothelial growth factor), immunofluorescent staining of angiogenic cells (CXCR4þ, SDF-1aþ, CD31þ, von Willebrand factor þ cells) and immunohistochemical staining of small vessel numbers in the ischemic area were significantly higher in group 4 than in the other groups (all P < 0.01). Furthermore, laser Doppler showed that the ratio of ischemic/normal blood flow was remarkably higher group 4 than in group 3 by days 14 and 28 after the CLI procedure (all P < 0.01). Conclusions. Sitagliptin therapy enhances circulating angiogenic cell numbers, angiogenesis and blood flow in the CLI area.
Relation:	Cytotherapy, 2013; 15: 1148e1163
Appears in Collections:	[Department of Nursing] Papers

Files in This Item:

File	Description	Size	Format
sitaglitpin.pdf	fulltext	4133Kb	Adobe PDF	0	View/Open

View Licence

Loading...